BRAF and melanoma: To determine if stable MALAT1 RNA levels are a common requirement in melanoma, we applied MALAT1-ASO treatment to a group of NRAS- and BRAF-mutant melanoma cell lines in vitro, including primary derived cell lines and cell lines with acquired resistance to the MEKi trametinib.